New research from Yale has uncovered an unexpected mechanism that challenges the long-standing view of brain circuits involved in hunger and weight control. Scientists had generally thought that agouti-related peptide (AgRP) neurons, which are well known for stimulating hunger, worked mainly against weight loss. However, their findings suggest something very different: during treatment with GLP-1 drugs such as Ozempic, these neurons appear to be recruited to help maintain fat loss.
The research was published in the journal Proceedings of the National Academy of Sciences (PNAS). The study found that when AgRP neurons were eliminated in mice genetically engineered to lack them, GLP-1 drugs were no longer able to sustain weight loss. Additionally, rather than being suppressed by semaglutide, the AgRP neurons were activated. This indicates a more complicated response inside the brain than previously recognized. When GLP-1 treatment creates a calorie deficit, the brain appears to respond by increasing the activity of AgRP hunger neurons, which also help coordinate the loss of fat.
The findings point to a more complicated response inside the brain than previously recognized and could provide an important foundation for developing the next generation of obesity treatments. Further research will be necessary to determine whether the same mechanism operates in humans. Identifying how GLP-1 medications influence the brain could provide new biological insights that could eventually help researchers design therapies that are even more effective or have fewer side effects.